Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
- None.
- None.
The Orphan Drug Designation (ODD) granted to CELZ-101 by the FDA is a pivotal event for Creative Medical Technology Holdings. This status is typically awarded to treatments for diseases affecting fewer than 200,000 people in the U.S. and can be a catalyst for accelerated development and regulatory approval. From a research perspective, the designation acknowledges the potential of CELZ-101 (ImmCelzTM) to address the unmet need in brittle Type 1 diabetes management, particularly in preventing allograft rejection post pancreatic islet cell transplantation.
CELZ's approach, which involves the use of enhanced regulatory T cells (Tregs), is particularly noteworthy. Tregs play a crucial role in maintaining immune tolerance and their application in this context could revolutionize the standard of care by reducing or eliminating the need for lifelong immunosuppression, which is fraught with significant side effects and risks. The proprietary process of expanding and enhancing Tregs may set a new precedent in personalized medicine and cell-based immunotherapies.
For investors, the ODD is a positive signal that could potentially enhance the valuation of Creative Medical Technology Holdings. The benefits accompanying the designation, such as tax credits, exemption from certain FDA fees and the possibility of seven-year market exclusivity upon drug approval, are significant financial incentives. These advantages can reduce the cost of drug development and increase the attractiveness of CELZ-101 to potential partners or acquirers.
The market exclusivity, in particular, is a critical competitive advantage that can prevent competitors from entering the market with similar therapies, thereby potentially increasing the return on investment for CELZ and its shareholders. Moreover, the progress of CELZ-101 through the regulatory pathways can be a driver for stock performance, as milestones achieved can often lead to positive reactions in the stock market.
The development of CELZ-101 has broader implications for the healthcare industry, especially within the niche of regenerative medicine. As the first orphan designated, synergistic cell-based immunotherapy for brittle Type 1 diabetes, it could set a benchmark for innovation in this sector. The therapy's potential to induce operational tolerance in islet cell transplantation represents a leap forward in treatment paradigms.
Furthermore, the focus on personalized medicine aligns with industry trends towards more patient-specific therapies. The success of CELZ-101 could also stimulate additional research and investment into related areas of regenerative medicine and immunotherapy, potentially leading to advancements in the treatment of other autoimmune and alloimmune conditions.
CELZ-101, also known as Supercharged Treg Biologic Immunotherapy (ImmCelzTM), represents a state-of-the-art approach in personalized medicine, utilizing the patient's own regulatory T cells (Tregs) to combat autoimmune and alloimmune responses that can destroy insulin-producing cells. This innovative therapy is based on a proprietary process that not only expands Tregs but also enhances their functionality, offering a promising solution to reduce the need for lifelong immunosuppression.
Timothy Warbington, CEO of Creative Medical Technology Holdings, stated, "The FDA's Orphan Drug Designation for CELZ-101 underscores our commitment to developing groundbreaking therapies. This important milestone propels us closer to offering a lasting solution for those grappling with the everyday hurdles of brittle Type 1 diabetes, marked by erratic fluctuations in glucose levels. It harmonizes with our mission to better patients' lives through the forefront of regenerative medicine. "
Dr. Courtney Bartlett, DNP, AGACNP-BC, CCRP, Director of Clinical Development, commented, "The development of CELZ-101 is a major step forward in the realm of cell-based immunotherapy. It addresses the critical need for more effective treatments in brittle Type 1 diabetes by aiming for operational tolerance in islet cell transplantation, potentially freeing patients from the burden of lifelong immunosuppression. We believe this is the first orphan designated, synergistic cell-based immunotherapy for brittle Type 1 diabetes."
“The Orphan Drug Designation by the FDA highlights CELZ-101's potential to meet a significant unmet need in the prevention of allograft rejection during pancreatic islet cell transplantation which was recently approved by the FDA. This designation provides multiple important benefits to support the therapy's development including tax advantages, user fee exemptions, and the opportunity for market exclusivity following approval,” added Timothy Warbington, CEO of the Company.
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is dedicated to progressing CELZ-101 through the necessary regulatory pathways, with the goal of transforming the therapeutic landscape for patients in need of islet transplantation. This achievement underscores the company's dedication to leveraging the natural regenerative capabilities of the human body to create lasting health solutions.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is a biotechnology company dedicated to the advancement of identifying and translating novel, immediately deployable FDA registered, biological therapeutics in the fields of immunotherapy, endocrinology, urology, gynecology and orthopedics and is traded on NASDAQ under the ticker symbol CELZ.
Creative Medical Technology Holdings is at the vanguard of regenerative medicine, focusing on the development and commercialization of breakthrough therapies for unmet medical needs. With a robust portfolio of innovative treatments, Creative Medical Technology Holdings is reshaping the future of healthcare by marrying advanced scientific research with the body's natural healing mechanisms.
For further information about the Company, please visit www.creativemedicaltechnology.com.
Special Note Regarding Forward Looking Statements
NASDAQ Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306397066/en/
Company Contact
Creative Medical Technology
IR@CreativeMedicalTechnology.com
Investor Relations
Devin Sullivan, Managing Director
The Equity Group Inc.
dsullivan@equityny.com
Conor Rodriguez, Analyst
crodriguez@equityny.com
Source: Creative Medical Technology Holdings, Inc.
